Methylprednisolon Jenapharm

Methylprednisolone, the active ingredient in Methylprednisolon Jenapharm, is a corticosteroid presented as an oral tablet for systemic use. It reduces inflammation and modulates immune response in conditions such as rheumatoid arthritis, asthma, and lupus.

GNH USA supplies Methylprednisolon Jenapharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylprednisolone is used to treat inflammatory and immune‑mediated disorders across several disease families. - Rheumatoid arthritis: reduces joint inflammation and pain. - Asthma: decreases airway swelling and improves breathing. - Allergic reactions: mitigates severe hypersensitivity symptoms. - Dermatitis: lessens skin inflammation and itching. - Multiple sclerosis relapses: shortens duration and severity of neurologic attacks. - Systemic lupus erythematosus: controls systemic inflammation and organ involvement.

Methylprednisolone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Increased appetite and weight gain. - Insomnia or difficulty sleeping. - Mood swings or irritability. - Elevated blood glucose levels.

Serious or Rare Side Effects: - Adrenal insufficiency on abrupt discontinuation. - Severe infections due to immune suppression. - Osteoporosis and increased fracture risk. - Psychotic episodes or severe mood disorders. - Anaphylactic reactions.

Before initiating therapy, consider the following safety measures. - Infection risk assessment: evaluate for active or latent infections. - Blood glucose monitoring: especially in diabetic patients. - Tapering plan: avoid abrupt cessation to prevent adrenal crisis. - Avoid systemic fungal infections unless benefits outweigh risks. - Use the lowest effective dose for the shortest duration possible. - Store at below 25°C: keep in the original pack, protect from moisture.

Methylprednisolone can alter the activity of several concomitant medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase glucocorticoid exposure. - Live vaccines: risk of inadequate immune response. - Systemic antifungal agents (e.g., itraconazole): can raise systemic levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - NSAIDs: increased risk of gastrointestinal ulceration or bleeding. - Diabetes medications: may require dose adjustment due to hyperglycaemia.